ABUS vs. EWTX, ARWR, AMRX, MIRM, GMTX, MESO, IBRX, CNTA, HCM, and KYMR
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Edgewise Therapeutics (EWTX), Arrowhead Pharmaceuticals (ARWR), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Mesoblast (MESO), ImmunityBio (IBRX), Centessa Pharmaceuticals (CNTA), HUTCHMED (HCM), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.
Arbutus Biopharma vs.
Arbutus Biopharma (NASDAQ:ABUS) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation.
In the previous week, Edgewise Therapeutics had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 1 mentions for Arbutus Biopharma. Edgewise Therapeutics' average media sentiment score of 0.47 beat Arbutus Biopharma's score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.
Arbutus Biopharma has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.
43.8% of Arbutus Biopharma shares are owned by institutional investors. 4.0% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 24.1% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Arbutus Biopharma received 401 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. However, 72.34% of users gave Edgewise Therapeutics an outperform vote while only 71.08% of users gave Arbutus Biopharma an outperform vote.
Edgewise Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,137.65%. Edgewise Therapeutics' return on equity of -26.83% beat Arbutus Biopharma's return on equity.
Arbutus Biopharma currently has a consensus price target of $5.50, suggesting a potential upside of 60.68%. Edgewise Therapeutics has a consensus price target of $41.29, suggesting a potential upside of 52.51%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Arbutus Biopharma is more favorable than Edgewise Therapeutics.
Summary
Arbutus Biopharma beats Edgewise Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:ABUS) was last updated on 2/21/2025 by MarketBeat.com Staff
Free ABUS Stock Alerts